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Abstract
Liver disease is one of the major chronic disabilities around the world. It is known that 
global casualties are increasing because of virus C infection, alcohol consumption, or non-
alcoholic circumstances. One of the main derived comorbidities of liver disease is the hepatic 
encephalopathy (HE), a severe neuropsychological syndrome derived from the acute or 
chronic liver disease. A key feature accounting for HE symptoms in cirrhotic patients is 
brain edema, which is triggered by hyperammonemia. In basal conditions, ammonia can be 
metabolized in the central nervous system (CNS) by astrocytes, which synthetize glutamine 
using ammonia and glutamate as substrates. In hyperammonemic conditions, astrocytes 
synthetize large amounts of glutamine generating a hyperosmotic condition, inducing these 
cells to become swollen in shape, invoking the characteristic symptom clinically manifested 
in patients with HE, as brain edema; this condition is regulated by water channels called 
aquaporins (AQPs) and by other molecules such as myoinositol. Experimental evidence 
suggests that some small non-coding RNAs may regulate AQPs expression both in vivo an 
in vitro and that some pharmacological interventions improve cognitive impairment in cir-
rhotic patients. It is undeniable that astrocytes and the different signaling pathways beneath 
its plasma membrane play a crucial role in liver disease-derived HE and represent some of 
the novel pharmacological targets to treat comorbidities of the liver disease.
Keywords: liver, hyperammonemia, encephalopathy, astrocytes, astrogliosis
1. Introduction
1.1. General aspects of liver disease and hepatic encephalopathy
Liver disease is one of the leading non-infectious pathologies affecting people around the 
world. In its report from 2015, WHO indicates that the advanced form of liver disease, mean-
ing cirrhosis, is among the 20 most frequent (2%) causes of death (~1.62 × 106) around the 
globe (http://www.who.int/). Hepatic encephalopathy (HE) is a pathological condition that 
© 2018 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativeco mons.org/licen es/by/3.0), w ich permits unrestricted use,
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represents the neuropsychiatric disorder derived from liver disease. It is known that about 
80% of patients with liver disease (depending on severity), may develop HE, which represents 
one of the major complications leading to death in about 90% of patients with acute liver fail-
ure (ALV) [1]. HE has been classified by the Hepatic Encephalopathy consensus Group, at the 
World Congress of Gastroenterology in 1998, in type A, associated with ALV; type B related 
to porto-systemic bypass; and type C related with chronic liver disease, mainly cirrhosis [2]. 
Further classification includes the severity of symptoms that includes the subcategory called 
covert (CHE, also known as minimal), persistent (PHE), and overt (OHE). The former is mild 
in manifestations and is hard to diagnose without specific neurophysiological and neuropsy-
chological tests, such as the visual-based flicker test, the psychometric hepatic encephalopathy 
score (PHES), the repeatable battery for assessment of neuropsychological status (RBANS), the 
inhibitory control test (ICT), the cognitive drug research (CDR), and the most recent STROOP 
App test (EncephalApp_Stroop), a practical smartphone App tool for HE screening to be used by 
the own patients [3, 4]. The PHE and OHE involve more specific clinical symptoms, including 
seizures, hyperreflexia, rigidity, myoclonus (sudden involuntary jerking of a muscle or a group 
of muscles), asterixis (hand tremor when wrist is extended), and stupor, which can be detected 
or reported by the clinician or patient as well [5]. In all of these cases, the main gross causative 
is the liver failure and the metabolic pathways affected thereafter. In general terms, HE is a 
debilitating condition in which patients gradually became less psychologically independent 
and more psychiatrically dependent. The majority of the symptoms in HE are triggered by 
molecular events within the central nervous system (CNS), and several hypotheses have been 
proposed in order to understand the pathophysiology. Some of them suggest that metabolites 
such as ammonia, myoinositol, glutamine, manganese, inflammatory mediators (IL-1, IL-6, 
and TNFα), and amino acids (Tyr, Phe, Val, Ile, and Leu) [6], regarding its effects over astro-
cytes and neuronal cells, are responsible of the clinical manifestations of the disease [6–8].
2. Astrocytes as mediators of the pathophysiology of HE
In this and further sections, we will try to introduce to the reader into a review about recent 
findings that illustrates how the physiological functions of the liver, or to a better extent, a 
lack of them, may harm at different levels, the metabolic and physiological homeostasis over 
brain cells and function.
2.1. Ammonium metabolism
The liver is responsible to detoxify the majority of endogenous or exogenous toxic compounds 
produced by the metabolic or catabolic activity within the organism, including pharmacologi-
cal metabolites, ammonium, bilirubin, bile salts, etc. Several factors may affect liver functions, 
such as increased consumption of a fat diet, another one is the chronic alcohol abuse; while 
the infection by hepatitis C virus (HCV), pharmacological intoxication (mainly paracetamol), 
complete the pathological scenario. The fatty liver, also known as steatosis (non-alcoholic fatty 
liver disease or NAFLD), has been called the first hit in liver damage, which when not prop-
erly attended, could result in a chronic inflammation or steatohepatitis (NASH). NASH could 
evolve to fibrosis and eventually to a more critical stage, cirrhosis. Cirrhotic patients suffer a 
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wide spectrum of comorbidities [9]. Among them is hepatic encephalopathy (HE), a debili-
tating psychological condition where the patients present a variety of symptoms including 
loss of memory, mild or manifested tremors, and most importantly, increased plasma levels 
of ammonia. In basal conditions, ureotelic organisms like humans, should contend with the 
ammonia derived from the gastrointestinal bacterial activity and muscle metabolism, by con-
verting it to carbamoyl-phosphate (CP), a substrate of the urea cycle, CP is then converted to 
citrulline, the precursor of arginosuccinate; arginosuccinate is then transformed to arginine 
and by the action of arginase, arginine is converted to urea and ornithine; all of these reactions 
takes place within the mitochondria and cytosol of the hepatocytes, resulting in the release of 
urea into the bloodstream and then in urine [10]. However, in pathological conditions like cir-
rhosis, hepatocytes are unable to produce urea; therefore, ammonium in its form of gas (NH
3
) 
easily diffuses to the blood brain barrier (BBB). Once within CNS, ammonium is metabolized 
primarily by the astrocytes, a group of specialized glial cells capable of modulate inhibitory 
and excitatory neurotransmission. In its form of ion (NH
4
+), ammonia reaches the astrocytes 
where a different transporter mediates its translocation throughout the plasma membrane. 
Among this transporters are the Na+/K+-ATPase pump, the Na+/H+-ATPase antiporter and 
Na+/K+/2Cl−, K+/Cl− symporters [5]. Astrocytes metabolize the ammonium by the so-called 
glutamate-glutamine cycle (GGC). The GGC produces glutamine (Gln) through the action of 
glutamine synthetase (GS), delivering it to neighboring glutamatergic neurons (Figure 1). In 
neurons, glutamine is subject to the opposite reaction, mediated by the enzyme glutaminase, 
whose products are glutamate and ammonium. Glutamate is packaged into synaptic vesi-
cles and released to the synaptic cleft in response to electrochemical stimulus, while ammo-
nium is released to the extracellular space [11]. Once released, glutamate binds to ionotropic 
(N-methyl-d-aspartate (NMDA) or AMPA) receptors, or metabotropic (mGluR1 and mGluR2) 
receptors in the postsynaptic neuron and astrocytes [11]. Unbound released glutamate can be 
Figure 1. The glutamine (Gln)-glutamate (Glu) cycle within astrocytes. Glutamine synthase (GS) mediates the reaction of 
ammonia (NH4+) and Glu to produce Gln. Gln is then exported by a specific transporter (illustrated here as a small black 
cylinder) to the glutamatergic neurons near the astrocyte. The cycle completes when Glu is released to the synaptic cleft 
and then binds to NMDA receptors or is recaptured by astrocytes to began the cycle. See text for details.
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recycled when  captured by the excitatory amino acid transporters (EAAT) located in the astro-
cytes membrane. These events represent the final step in the GGC.
On the other hand, besides GGC, astrocytes may use other systems to titrate ammonium from 
bloodstream. Those based in the use of the branched chain amino acids (BCAA) on one side, or 
the use of L-ornithine and L-aspartate in the other. In the first case, BCAA are metabolized by 
the enzyme branched-chain amino acid transaminase (BCAT) particularly enriched in the cyto-
plasm and axons of glutamatergic and GABAergic neurons [12]; cytoplasmic BCAT enzymati-
cally mediates the synthesis of branched-chain ketoacids (BCKA), which in turn generates both, 
a precursor for the tri-carboxylic acid cycle (TCA) in the form of Acetyl-CoA and the excitatory 
amino acid glutamate; glutamate in turn, can be metabolized by means of the GS to produce 
glutamine; glutamine is deaminated by the phosphate-activated glutaminase (PAG) which is 
also present in the cytoplasm of neuronal and glial cells [13]. The second one, the L-Ornithine 
and L-Aspartate system, operates to generate glutamate by means of the ornithine- or aspartate-
aminotransferase (OAT, AAT); both enzymes are enriched in the skeletal muscle, thus contrib-
uting to stimulate the glutamine production in this tissue by the GS, diminishing the ammonia 
derived from circulation [5]. L-ornithine and L-aspartate represent one of the most frequent 
therapeutic approaches to improve ammonia levels in cirrhotic patients, as we shall see later.
2.2. Astrocytes and the effect of hyperammonemic conditions within CNS
It is known that NH
4
+ and K+ have comparable physical and chemical properties, so that 
any change or increase in NH
4
+ concentrations may activate the Na+ transport by the Na+/
K+-ATPase pump, leading to abnormal neurotransmission in neurons or even astrocytes [14]. 
NH
4
+ enters to the astrocytes and induces the increase in the activity of the GS; this event 
results in the accumulation of glutamine. As intracellular glutamine concentrations rise, the 
osmotic pressure does it in parallel, provoking the astrocytes to become swelling and to acti-
vate two main mechanisms to counteract this morphological change [15]. The first one consists 
of the release of an osmotic regulator, myoinositol; myoinositol leaves the astrocyte to redress 
the osmotic balance within the cell to prevent astrocyte and cerebral edema; while the other 
one is to increase the activity of the water channels called aquaporins (AQPs). One of the main 
water channel transporters related with regulation of the osmotic response in astrocytes, is the 
aquaporin 4 (AQP4) [16]. It has been reported that AQP4 increases its activity under hyper-
ammonemic conditions, allowing the H
2
O molecules to enter into the cell, thus relieving the 
osmotic pressure induced by the accumulation of glutamine [17]. Until then, it was not clear 
whether the increased activity of AQP4 was the result of a higher transcriptional activity or an 
increased rate of mRNA translation [18]. Evidence in favor of both options had been reported. 
In two separate reports, Jalan et al. and Norenberg et al. demonstrated independently the 
increased expression of AQP4 protein, in a chronic or acute in vivo models of liver failure 
based on the bile duct ligation (BLD) or the use of thioacetamide (TAA) or acetaminophen 
(AAP), respectively [19, 20]. Accordingly, in vitro evidence indicates that ammonia-treated 
astrocytes also increase AQP4 protein levels [21]. On the other hand and in favor of tran-
scription, additional evidence indicates that ammonium or mannitol, both osmotic stressors, 
increase the expression of AQP4 mRNA in vitro and in vivo, probably mediated by the p38-
MAPK signaling pathway, which stimulates the tonicity-enhancer binding protein (TonEBP) 
to interact with the responsive enhancer element (TonE) over the AQP4 gene promoter region 
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[17, 19, 22]. Further evidence indicates that other AQPs are direct targets of the hypothalamic 
arginine-vasopressin peptide (AVP) and the angiotensin II (ANGII) hormone; for instance, 
AVP controls the expression of AQP2 in the renal collecting duct cells under basal conditions, 
increasing the intracellular levels of cAMP that in turns modifies the activity of one of its 
targets, PKA; PKA phosphorylates the CREB protein allowing its translocation to the nucleus 
and its transcriptional activity [23]. It remains to be elucidated if AQP4 gene expression in 
hepatic encephalopathy conditions is also regulated by similar mechanisms.
As we have seen, hepatic failure is closely related to astrocyte low grade and brain edema 
mediated by water movement throughout the AQP4 channel. Among the pathogenic fac-
tors contributing to aggravate this condition are the free radical production, the MAP-kinase 
activity, and the induction of the mitochondrial permeability transition (MPT) process. MPT 
is well known to occur in response to the sudden intra-cytoplasmic increase of molecules 
around 1.5 kDa in size that enters the mitochondria mediated by the so-called permeabil-
ity transition pore (PTP), which is located at the inner membrane [24]. These phenomena 
critically compromises mitochondria homeostasis and the metabolic function of many crucial 
processes like the TCA and ATP synthesis, promoting the generation of reactive oxygen spe-
cies (ROS). It seems that HE promotes the generation of ROS, therefore inducing the MPT due 
to the oxidative stress, because indirect evidence demonstrates that antioxidants are able to 
reduce MPT. Norenberg et al. demonstrated that MPT is involved in the ammonium-induced 
astrocyte swelling after their in vitro experiments based on the use of cyclosporine A (CsA), a 
well-known inhibitor of MPT [25]; in this study, the expression of the AQP4 protein was also 
inhibited by CsA, indicating a plausible crosstalk between different signaling pathways, such 
as the MAP-kinases or that conformed by the protein kinase A (PKA)/CREB, both of which 
might be related to the control of cell swelling in hyperammonemic conditions.
2.3. Systemic and local inflammatory pathway effects on astrocyte disturbances
Another important mechanism of regulation of astrocyte physiology in response to hepatic 
failure is the activation of the pro-inflammatory response. In recent years, an increasing role 
of the inflammatory-related pathways in response to ammonia-induced brain dysfunction 
has been reported. The cytokines promoting brain damage are TNFα, interlukin-6 (IL-6), 
interlukin1-beta (IL-1β), IL-18, and many others. However, there is controversy about the role 
between these pro-inflammatory cytokines in both acute and chronic hepatic failure. Several 
groups have provided evidence of a positive correlation in this interaction in human subjects 
or animal models. In 2007, Wright and colleagues determined the TNFα, IL-6, and IL-1β artery 
blood levels and found a positive correlation of these cytokines with intracranial pressure in 
ALF-affected humans [26]. Further evidence indicates that the same cytokines are elevated, 
at least at the transcriptional level, in the brains of a rat ALF model [27]. A recent interest-
ing proposal about the role of these circulating inflammatory interleukins indicates that they 
might interact with certain blood-brain barrier (BBB) endothelial cells to reach the CNS, acting 
synergistically with ammonia. This synergistic model has been expanded through the identi-
fication of additional factors such as GABA produced by certain bacterial families within the 
gut, contributing to modify the GABAergic tone that reach the CNS via the vagal afferent path-
way [28]. In view of these facts, systemic inflammation is in part responsible for the astrocyte 
and neuronal network alterations in both acute and chronic liver disease. A major player in 
Astrocyte Pathophysiology in Liver Disease
http://dx.doi.org/10.5772/intechopen.72506
211
the systemic inflammation effects over CNS in these pathologies is a member of the danger-
associated molecular patterns (DAMPS) called high mobility group box protein 1 (HMGB1), 
which in basal conditions regulates transcriptional activity [29]; however, in pathological con-
ditions, it can be released passively from damaged cells into the extracellular space in response 
to pro-inflammatory stimuli, such as LPS; HMGB1 can also be actively released by a JAK/STAT 
acetylation-mediated process, from immunocompetent cells [30]. In a recent study, Ohnishi 
et al. showed that HMGB1 significantly decrease the expression of AQP4 mRNA and protein 
in cultured astrocytes; conversely, the intra-cerebroventricular injection of HMGB1 in adult 
rats, slightly increase AQP4 protein expression and as expected, the brain edema; further, 
exposure of microglia to a HMGB had a significant effect over IL-1β mRNA expression and 
protein release, which apparently regulates AQP4 increased expression; the authors suggest 
that the pathway IL-1β-NF-κB-AQP4 in microglia might regulate the brain edema in response 
to HMGB1-mediated systemic inflammation [31]. Whether this pathway might occur with 
other pro-inflammatory cytokines such as TNFα, IL-6, or IFNγ, remains to be investigated.
The unusual extracellular histone proteins represent another piece in the puzzle of the systemic 
inflammation response. It has been showed that in ALF or HBV infected patients, increased 
concentrations of circulating histones correlates with an immunostimulatory effect, leading 
to multiple organ injuries [32–34]. In vitro experiments with hepatic or monocyte cell lines 
stimulated with sera obtained from ALF patients, elicit cell death or release of inflammatory 
cytokines, respectively; interestingly, these effects were abolished with heparin—a histone-
binding anticoagulant—suggesting that histone proteins are key players in the cellular injury 
and systemic inflammation observed in ALF-affected patients [32]. In addition to previously 
described consequences of the liver disease, including hyponatremia, sepsis, variceal bleeding, 
and renal failure; is the activation of microglial cells, the resident macrophages of the brain. 
Microglia increase the synthesis and release of inflammatory cytokines in a process called 
microgliosis [35]. Microgliosis is part of the most general response gliosis, which involves the 
astrocytes, the microglia, and oligodendrocyte cells; microgliosis is the local response to brain 
insults and typically represents the scar-promoting mechanism within the CNS.
Along with systemic and local brain inflammation, the increased ammonia and manganese 
levels in the brain also alter the TCA cycle, promoting lactate accumulation and the promotion 
of dopaminergic cell death, as well as the generation of reactive oxygen species (ROS) in basal 
ganglia, and contributing in this way to the parkinsonism-like behavior and cognitive impair-
ment observed in cirrhotic patients [36]. In this line of evidence, oxidative stress is thought to 
be of relevance for ammonia toxicity in HE. Molecular studies indicate that acute ammonia 
loading, mechanical or drugs stressors like hypo-osmolarity, diazepam, and TNFα, in vitro and 
in vivo, increases ribonucleic acid (RNA) oxidation. Among the oxidized RNA species, the 18 s 
rRNA and the glutamate/aspartate transporter (GLAST/SLC1A3) mRNA have been described; 
strikingly, the cerebral RNA oxidation in liver-injured rats predominates in the transport RNA 
granules located in close vicinity with postsynaptic spines, where learning and memory-associ-
ated protein synthesis occurs [37]. These data strongly suggest that ammonia-induced inflam-
mation and RNA oxidation might impair both cognitive events in cirrhotic patients. In addition, 
it has been demonstrated that ammonia inhibits astrocyte proliferation promoting senescence 
both in vitro and in vivo, by means of the multidrug resistance-associated protein (Mrp) 4 and by 
a p38/MAPK-dependent activation of the cell cycle inhibitor genes GADD45α and p21 [38, 39].
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2.4. The role of the intestinal microbiota in the gut-liver-brain axis
The intestinal microbiota has evolved as a new and relevant player in the pathogenesis of sev-
eral intestinal and non-intestinal diseases. As the liver is the organ in closest contact with the 
intestinal tract, it is potentially exposed to bacterial components and metabolites. In physi-
ological conditions, nutrients and bacterial compounds translocate to the liver via the portal 
circulation and contribute to the host homeostasis. As the epithelial wall and mucus layer act 
as physical barrier to impede that the most of the bacterial components or even bacteria reach 
the blood flow, it is usually accepted that a small quantity of these compounds enter the portal 
venous flow, and a tight balance on the immune response is achieved in order to fight against 
potential exogenous insults. However, in pathological conditions, such a physical barrier can 
become more permeable to bacterial components, specially lipopolysaccharide (LPS), flagellin, 
peptidoglycan, and microbial nucleic acids [40]. Evidence about the effect of gut microbiota 
over hepatic physiology has been demonstrated. In 2010, Gupta and co-workers found that 
small intestine bacterial overgrowth (SIBO) was a hallmark in cirrhotic patients suffering of HE 
[41]; in the same year, Jun et al. published evidence about the direct association of SIBO with the 
peripheral founding of bacterial DNA in cirrhotic patients [42]; later on, in 2012, Henao-Mejia 
et al. demonstrated that genetic deficiency of inflammasome, a protein complex considered 
the sensor of endogenous and exogenous pathogen-associated molecular patterns (PAMPS), 
induced the accumulation of bacterial components in the portal circulation, with the conse-
quent liver damage effect [43]. One important fact about the bacterial overgrowth in cirrhotic 
patients is that the translocation of bacteria or any of its components promotes and aggravates 
the liver illness. There are several reports indicating the differences in the fecal microbiota of 
various populations around the globe, specifically in patients with liver cirrhosis in comparison 
with healthy subjects. In general, these studies coincides in founding that the phyla Proteobacteria 
and Fusobacteria, significantly increases in cirrhotic patients, compared with its healthy coun-
terparts [44–46]; while at the genus level, the pathogenic Enterobacteriaceae, Alcaligenaceae, 
Porphyromonadaceae, Veillonellaceae, and Streptococcaceae families prevail and the beneficial taxa 
such as Lachnospiraceae and Bifidobacteriaceae, diminished in cirrhotic samples [45, 47]. In our 
laboratory, we conducted a pilot study in order to explore the changes in the microbiota of 
cirrhotic patients. Preliminary results indicate that some of these taxa previously reported are 
also present in the cirrhotic group of VHC-infected patients based in Mexico city; but we have 
also found that some other taxa have not been reported in other population (unpublished data); 
our findings are in concordance with the idea that additional variables, such as ethnicity or 
geographical location and even food ingestion habits, should be taken into account in order 
to interpret microbiome-derived studies, which eventually can be used in future clinical trials.
Another significant consequence of SIBO is the higher tendency of the microbial community 
to increase the synthesis and release of organic compounds with a metabolic effect over a wide 
number of host cells. For example, it has been demonstrated that ingestion of L. rhamnosus, 
diminishes the expression of gamma-amino-butyric acid (GABA) receptor (GABAB) in the cin-gulate and prelimbic cortical regions of mice brain; this GABAB regulation implies a direct effect over neuronal physiology, which reflects in less anxiety and more antidepressant-like behavior 
in mice; moreover, vagotomised mice were unable to respond to L. rhamnosus, indicating that 
vagus nerve acts as an interface between gut bacteria and the brain [28]. Whether these bac-
teria produce a GABA-like neurotransmitter or directly modify the fire-threshold from vagus 
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nerve remains a matter of study. Nowadays, molecular studies contributing to explain partially 
the mechanics behind the role of GABA and the intestinal microbiota have been published. 
Butterworth and colleagues in 1990 and 2008, found that brain samples from cirrhotic patients 
who died from HE, had unusual elevated levels of the peripheral-type benzodiazepine recep-
tors (PTBZR) and of neurosteroids such as allopregnanolone (ALLO) or tetrahydrodeoxycor-
ticosterone (THDOC) [48, 49]; interestingly, these neurosteroids are synthesized in the brain 
following activation of the translocator protein (TSPO), whose main activity is the cholesterol 
transport through the mitochondria, where stimulates the steroid biosynthesis [50]. Further 
evidence from Noremberg and co-workers indeed, indicates that astrocyte exposure to ammo-
nia and manganese, significantly increase the TSPO activity, at least in vitro [51], indicating that 
neurosteroids are one of the main metabolites synthetized in response to hyperammonemic 
conditions as a result of dysbiosis and a lack of a functional urea cycle. However, there is some 
evidence indicating that some other metabolites produced by gut microbiota, such as the bile 
acids, tryptophan precursors, serotonin and catecholamine, might be able to signal through 
membrane receptors located in local cells of the gut epithelium or by a neurocrine or endocrine 
pathways; among these metabolites are the carbohydrate derivatives butyrate, acetate and pro-
pionate, which might be converted to short chain fatty acids (SCFAs); these SCFA in turn can 
reduce food intake and modulate the immune system response in the host [52, 53]. Different 
reports indicate that SCFAs are present in the enteroendocrine cells and on neurons of the sub-
mucosal and myenteric ganglia [54, 55]. Besides the SCFAs, it cannot be ruled out the possibil-
ity that some Gram-positive cell wall components are also capable of inducing neuronal or glial 
cell damage within the CNS of cirrhotic patients. In 2005, a report indicated that lipoteichoic 
acid (LTA) and muramyl dipeptide from Staphylococcus aureus induce a strong inflammatory 
response that ultimately lead to neuronal death by increasing nitric oxide (NO), superoxide 
(O
2
-), peroxynitrite (ONOO-), TNFα, IL-1β and IL-6, within astrocytes and microglia [56].
Here, we can say that the net result of the so-called “dysbiosis” in cirrhotic patients is that a 
plethora of metabolic compounds like urea, methanol, short-chain fatty acids (SCFAs), and 
other volatile compounds are delivered or restricted to the host via the gastrointestinal tract. 
Altogether, these data indicate that intestinal bacteria play key roles in development and 
pathophysiology of hepatic liver over the CNS.
2.5. Genetic and epigenetic effects induced by HE in astrocytes
Epigenetic modifications are heritable and reversible stable marks that do not modify gene 
sequences per se, but have tremendous impact over the gene expression process. These marks 
allow the genome to adapt its transcriptional repertoire to different cellular and molecular 
conditions in response to environmental cues for fine-tuning of gene expression, and encom-
pass a myriad of processes including histone, DNA and RNA modifications. One of the best-
studied DNA modifications is the methylation (5-mC) and 5-hidroxy-methylation (5-hmC) of 
cytosine bases at the CpG dinucleotide sequence, mediated by the DNA methyltransferase 
(DNMT) or by the translocated in liposarcoma, Ewing’s sarcoma and TATA-binding protein-
associated factor 15 (TET)-family of proteins, respectively [57]. It is widely accepted that the 
first mark, 5-mC, is a negative signal for gene expression to occur, while the 5-hydroxy-mC 
indicates the opposite. The role of DNA methylation dynamics within astrocytes is not yet 
known, at least in the context of HE derived from liver disease; however, specific data indicate 
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that the NMDA receptor NR2B gene is negatively regulated by the neuron restrictive silencer 
factor (NRSF) in ethanol-exposed cortical neurons in vitro [58]; although specific analysis in 
this study indicates that NRSF directly interacts with the NR2B gene promoter region, there 
is no evidence of how ethanol regulates NRSF gene expression. Further evidence about the 
role of methylation or acetylation of glutamatergic or gabaergic-mediated signaling pathways 
affected by hyperammonemia remains to be elucidated.
On the other hand, we know that non-coding RNAs (ncRNA) are important players in epigen-
etic mechanisms regulating cell fate and metabolism. Among the ncRNAs with relevant physi-
ological roles are small RNAs and the long non-coding-RNAs (lncRNAs). A variant of small 
RNAs includes the microRNAS (miRNAs), which are beginning to acquire significant roles in 
coordinating astrocyte gene expression. miRNAs are small RNAs (~22 nt in length) that controls 
gene expression through their binding to the 3′-untranslated region (UTR) in mRNAs, leading 
transcripts to degradation or translational repression [59]. Long noncoding RNAs (lncRNA) on 
the other side are sequences of about 200 nt in length, which regulate the expression of neighbor 
protein-coding-genes in a phenomenon called “transvection” (for a systematic review see [60]). 
In the last decade, there has been an increase in the number of reports demonstrating the role 
of both miRNAs and lncRNAs in the physiopathology of HE. Two of the first reports regarding 
the role of two specific miRNA in the regulation of astrocyte cell swelling came from Singapore; 
in 2010 and 2012, Jeyaseelan and colleagues published in separate papers that miR-130a and 
miR-320a directly affect the AQP4 expression in the CNS. In the first case, the role of miR-130a 
is a non-canonical regulation, because the repression mechanism occurs at the transcriptional 
level over the AQP4 M1 gene promoter [61], while the mir320a was described as a modulator of 
AQP1 and AQP4 in a model of cerebral ischemia [62]. In a more wide recent study, Häussinger 
and co-workers explored the global miRNA profile using NH4Cl stimulated rat brain astrocytes 
in vitro. They were interested in the ammonia-dependent senescence observed in astrocytes and 
its relationship with miRNAs. By means of miRNA array experiments, they found that 43 of 
336 miRNAs were significantly downregulated in hyperammonemic conditions, six of which 
(miR-31a-5p, miR-221-3p miR-221-5p, miR-222-3p, miR-326-3p, and miR-365-3p) seem to bind 
and regulate the mRNA encoding the heme oxygenase 1 (HO-1) protein; four of these miRNAs 
(miR-31a-5p, miR-221-3p, miR-222-3p, and miR-326-3p) were prevented to be downregulated 
by NH4Cl treatment, when astrocytes were exposed to the glutamine synthase inhibitor, methi-
onine sulfoximine (MSO); moreover, the NADPH oxidase inhibitor, apocynin, fully prevented 
NH4Cl-mediated downregulation of the four miRNAs predicted to target HO-1, indicating that 
senescence is regulated by miRNA expression in cultured astrocytes and partly regulated by 
glutamine synthesis and NADPH-oxidase activity [63]. Data recently obtained in our labora-
tory indicate that three miRNAs (miR-29a-5p, miR-29b-3p, and miR-148b-3p) are repressed in 
brain tissue of a mouse model of liver cirrhosis. Interestingly, we found that the same miRNAs 
were downregulated in in vitro experiments using primary astrocytes incubated in the presence 
of NH4Cl (Figure 2); thus indicating that these miRNAs are strongly correlated with the physi-
ological regulation of AQP4, both in basal and pathological conditions. Future experiments will 
allow us to demonstrate whether overexpression of these miRNAs by means of systemic or 
direct injection in hyperammonemic conditions counteracts the astrocyte cytotoxic edema.
The lncRNAs, on the other hand, had been more less studied in the context of liver-associated 
CNS pathologies; however, in a recent study in which 35,923 lncRNAs were screened using 
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microarrays, Silva and colleagues found that 380 and 486 transcripts were upregulated or down-
regulated in a mouse model of acute liver failure. The authors found that some of these lncRNAs 
might be related to the cytokine-receptor interaction, MAPK, insulin, NFκB, and TNFα signal-
ing pathways, all of them related to the inflammatory response; the authors also found that 
the lncRNA uc007pjf.1 associated with a guanine nucleotide exchange factor (NET1), which 
regulates RhoA, is involved in the cytoskeleton dynamics, suggesting a relationship of this fac-
tor with the astrocyte cell swelling observed in HE [64]; these data are of relevance because con-
tributes to corroborate the role of some genetic pathways already related with ALF and certainly 
established the roots to new discoveries; however, these findings are the result of a combination 
of cellular phenotypes within CNS and are hardly extrapolated solely to astrocytes, neurons, 
microglia or even to non-differentiated precursor cells residing in the frontal cortex; comple-
mentary in vitro or FACS-sorted cells experiments, should be carried out in order to acutely 
assign the contribution of each of these cell phenotypes to the physiopathology of liver disease.
2.6. Clinical data in osmoregulation and systemic infections in cirrhotic patients 
with HE
The maintenance of a constant cell volume is a critical problem of all cells. Cell swelling or 
shrinkage is undesirable for normal cellular function. Changes in the cell volume mostly 
occur due to changes in the extra or intracellular osmolarity. As most cell membranes are 
freely permeable to water and do not possess water pumps in their membranes, cells will 
shrink or swell in response to changes in the tonicity of the extracellular fluid (ECF) [65]. 
Cells will shrink in a hypertonic ECF, while they swell in a hypotonic ECF. Similarly, when 
the tonicity of the intracellular space of the cells increases, the cells try to compensate it and 
increase the osmolarity by the uptake of water from the ECF—and consequently swell. Extra- 
and intracellular osmolarity is determined by the concentrations of several compounds, such 
Figure 2. The expression of miR-29 and miR-148 diminished in response to hyperammonemia in vivo and in vitro. Total 
RNA extracted from the whole brain of bile duct ligated (BDL) mice or control mice (Sham), as well as primary astrocytes 
(CD1) or the astrocytoma cell line T-98 in the presence or absence of NH
4
Cl, was used to evaluate the expression by 
means of qPCR. The data represent the mean expression of at least three replicates in each case (unpublished data).
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as ions, amino acids, etc. Consistent with the adaption against the rise of intracellular osmo-
larity in patients affected by CLF, it has been proposed that reductions in brain concentrations 
of myoinositol are implicated in the pathogenesis of ammonia-induced brain edema [66].
In the same line of evidence, it is difficult to elucidate whether the release of taurine (an atypical 
aminoacid with osmoregulatory properties) from the astrocytes to the ECF is an osmoregula-
tory response to increased intracellular glutamine and/or cell swelling, since other mechanisms 
that increased intracellular osmolarity may lead to the cellular release of taurine and taurine 
may also be released from neurons. Taurine has been related with reversal of hepatic hyper-
tension in a rat model of liver cirrhosis; in a study from 2009, Liang and colleagues found that 
natural taurine significantly decreased the portal venous pressure, resistance and flow, and 
markedly decrease the nitric oxide (NO) and cyclic guanine-monophosphate (cGMP), with a 
concomitant reduction in the pathological status of liver tissue damage and the expression of 
collagen 1 (COL-1), COL-III, and transforming growth factor-β1 (TGF-β1) [67]. Taurine also 
have clinical uses in the form of a hydrophilic bile acid called tauroursodeoxycholate (TUDCA) 
for treatment of primary biliary cirrhosis (PBC). In a randomized cross-over study with 12 
female patients suffering from PBC, the use of TUDCA showed to improve the enrichment of 
biliary ursodeoxycholate (UDCA) and was better absorbed than ursodeoxycholate and under-
goes less biotransformation than UDCA, thus suggesting that TUDCA is clinically relevant 
for the treatment of cholestatic liver diseases [68]. As taurine is synthetized in both liver and 
brain it is plausible that HE might impact on taurine metabolism and biological action. Several 
reports have indeed described the pathological disturbances in patients with chronic liver dis-
ease as well as in liver failure murine models. In both cases, the taurine concentrations were 
significantly diminished [69, 70]. Astrocytes synthetize and stored taurine, which is involved 
in ion movement across CNS, mainly K+ and Ca2+; therefore, is not rare to consider that neural 
excitability modifications in cirrhotic patients occurs. Evidence in favor of this hypothesis was 
reported in an experimental model of ALF, in which CSF taurine concentrations significantly 
increased in a positive correlation with early progression of HE [71]. As taurine has osmoregu-
latory actions any increase or decrease in its extracellular concentrations could have an impact 
in the pathogenesis of acute liver failure as has been demonstrated [72]. In contrast, taurine 
concentrations in chronic liver failure are not changed, but the release of taurine into the extra-
cellular space could represent a control mechanism for volume regulation of astrocytes [73, 74].
Another important metabolite that has been related with HE is the acidic calcium binding pro-
tein S100β, produced by astrocytes in the CNS and apparently secreted in response to oxidative 
stress, exerting its paracrine or autocrine effects on glia, neurons, and microglia [75–77]. S100β is 
a multifunctional protein that can be measured in basal conditions in CSF and is barely detected 
in circulating blood flow; however, in pathological conditions, its serum levels might increase, 
indicating neuronal or astrocytic damage. Our group and others have begun to investigate the 
diagnostic efficacy of S100β as a biomarker to detect low grade HE in cirrhotic patients. Recent 
findings from our laboratory indicate that cirrhotic subjects with OHE have higher serum lev-
els of S100β when compared with non-HE cirrhotic or cirrhotic patients with MHE or control 
subjects, and that 0.13 ng/mL of S100β is the best cut-off for the diagnosis of HE (83 and 64% of 
sensitivity and specificity, respectively) [78]. These results are in accordance with previous data 
in which S100β and neuron-specific enolase (NSE) were evaluated in a small Egyptian cohort of 
52 subjects, where 62 and 38% of 29 cirrhotic patients had HE grade 1 or 2, respectively; these 
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groups were compared with non-HE cirrhotic or healthy subjects. Here, NSE showed non- 
significant differences among the groups, but S100β was increased in serum samples from grade 
1 and 2 HE, compared with cirrhotic or healthy subjects; in addition, a significant positive corre-
lation was found between S100β levels and plasma ammonia, in all patients; the main conclusion 
in this report was that S100β serum levels could be a useful surrogate marker with more than 90 
and 50% of specificity and sensitivity, respectively, for detection of mild cognitive impairment 
in cirrhotic patients, before they progress to more advanced stages of HE [79]. In a similar study, 
Wiltfang et al. reported that a cut-off value of 112 pg./mL or 0.11 ng/mL of serum S100β, practi-
cally the same value found in our group of patients, is able to predict subclinical porto-systemic 
encephalopathy with a 100 and 57% of specificity and sensitivity, respectively [80].
Osmotic abnormalities account for the cognitive impairment in cirrhotic patients and some 
clinicians are using the magnetic resonance (MR) in order to clearly demonstrate a relation-
ship among water, manganese, glutamate, glutamine, and myoinositol levels and the degree of 
brain damage in patients with liver disease. MR might be useful to diagnose brain abnormali-
ties elicited by hyperammonemia, especially in specific regions like the globus pallidum and the 
temporal region. It has been documented that N-acetylaspartate (NAA) is a good biomarker for 
neuronal loss and phosphocholine (Cho) concentrations reflects phospholipid metabolism and 
osmotic regulation due to its role in membrane synthesis and myelin destruction. Low levels 
of Cho have been associated with osmotic changes in the brain of cirrhotic patients. The major-
ity of these metabolites have different echo times in MR spectroscopy with glutamate (Glu), 
glutamine (Gln), and phosphocreatine (PPC) being some of most constant correlation findings 
between patients with or without HE. However, in patients with OHE, the MR is difficult to 
perform because many confounding factors might co-exist, such as infection, renal failure, ane-
mia, alcohol consumption, and other factors [81]. Our group recently conducted a pilot study 
in which non-infected compensated, infected cirrhotic, and healthy patients were evaluated to 
assess for cerebral changes in myoinositol and NAA by means of proton magnetic resonance 
spectroscopy (1H–MRs). Here, we have found that 40 and 30% of the infected patients were 
by spontaneous bacterial peritonitis or urinary tract infection, respectively; we also registered 
a significant decrease of myoinositol levels in the temporal region of non-infected cirrhotic 
and infected cirrhotic patients when compared with the healthy control group; in addition, 
we found a similar pattern whit NAA, which significantly diminished in the former groups 
(Figure 3) (unpublished data). When we sought over basal ganglia, Creatine, Cho as well as 
myoinositol levels did also significantly diminished in infected cirrhotic patients; altogether 
these results strongly suggests that acute infection in cirrhotic patients contributes to regulate 
brain metabolites and may be a factor related with development of HE (unpublished data).
Besides those data indicating that brain metabolites are also implicated in the pathophysiol-
ogy of HE, another important issue in end-stage liver disease is the local blood flow. Cirrhotic 
patients with portal hypertension suffering ascites, hepatorenal syndrome and HE, usually 
also had distorted cerebral blood flow (CBF), which severely impact their skeletal muscle, 
brain, and kidney irrigation as a result of vascular resistance. It has been a long way since the 
1960s decade, when one of the first studies about cerebral hemodynamics in cirrhosis came 
into light [82]. Since then, a plenty of studies have contributed to understand the role of vas-
cular pressure over the pathology associated with HE. In 1969, Bianchi-Porro and co-workers 
reported that after portacaval shunt surgery, cirrhotic patients, had a significance increase in 
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CBF and a significant decrease in cerebral vascular resistance (a measure of CBF and metabo-
lism) and the metabolic rate of glucose and the glucose:oxygen quotient did also increase in 
these patients; the authors suggested that the increased CBF was related to metabolic prob-
lems, and that this increase accelerates the removal of toxic substances and allows the disposal 
of brain metabolites capable of neutralize toxic compounds [83]. It is now well accepted that 
cirrhotic patients have decreased CBF, portal hypertension, and splanchnic vasodilatation, 
associated with a hyperdynamic circulatory state, all of which can affect CBF. In a more recent 
study, we described a maneuver in which we used the transcranial Doppler (TCD) technique 
(transmission of ultrasound beam through the skull using a pulsed Doppler sectorial probe 
with a 2 MHz transducer), to measure in an non-invasive and reliable way, the cerebral auto-
regulation, meaning the physiological mechanisms that maintain CBF at an appropriate levels 
in response to vasoconstrictors or vasodilators and the middle cerebral artery (MCA) velocities. 
From here, two functional cerebral hemodynamic indexes were evaluated, (a) the pulsatility 
index (PI) which assesses the arteriolar vascular integrity and (b) the breath holding index 
(BHI), which measures cerebrovascular reactivity (CVR). We compared the TCD measures of 
cirrhotic non HE (n = 30), cirrhotic HE (n = 30) and healthy subjects (n = 30). Here, we found 
that major basal vessel integrity was not compromised because there were no differences 
among the three groups when the left and right cerebral arteries were evaluated. However, we 
observed significant differences in PI and BHI between cirrhotic and control subjects and when 
the compensated status was taken into account, the PI and BHI was significantly increased 
and decreased, respectively, when decompensated (CTP > 7 and MELD score ≥ 14) patients 
were compared with compensated and healthy groups. Similarly and more importantly, when 
HE status was included in the analysis, the results were the same as before, which means that 
disturbances in CBF is a novel pathophysiological pathway in HE, and opens an new way for 
treatment and prevention. Patients with decompensated cirrhosis or HE have a higher risk 
of cerebral hypoperfusion related with microvascular damage and the ability for autoregula-
tion, which is and important feature for systemic blood pressure sudden changes, particu-
larly hypotension, which can promotes HE [84]. These findings were similar to those reported 
by two separated groups, one located in Turkey, were 50 decompensated group of cirrhotic 
patients was compared with 50 healthy volunteers using the same TCD approach [85]; while 
other in China recruited a healthy control group (n = 40), a cirrhotic without HE group (n = 52), 
a cirrhotic with MHE group (n = 21) and a cirrhotic with OHE group (n = 19) [86]. Here, in the 
first case, the authors analyzed the spectra signal derived from the systolic velocity, diastolic 
Figure 3. Cirrhotic infected patients have significant abnormalities in the glutamine/glutamate (Glx) ratio and NAA 
brain levels. See text for details.
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velocity, mean flow velocity (MFV in cm/s), pulsatility, and the resistive indexes (PI = Peak sys-
tolic velocity (V
p
) – end-diastolic velocity (V
d






) of intracranial arteries. 
Patients with cirrhosis had a lower MFV compared to control healthy group, while cirrhotic 
patients had a higher PI and RI values and a positive correlation exists with the model for end-
stage liver disease (MELD) score and the RI values of patients with ascites, which were higher 





, PI, and RI, as well as the serum ammonia levels, were decreased in the group of cirrhotic 
patients with MHE subject to lactulose treatment, when compared with the placebo group, 
while a positive correlation was found between ammonia and PI, RI, cognitive test results and 
V
d
; authors propose that cerebral hemodynamics is related with the severity of HE and that 
lactulose treatment is able to significantly improve this parameter in cirrhotic patients [86].
3. Novel pharmacological findings over HE treatment
Despite being one of the most frequent and best studied associated pathologies of liver dys-
function, HE still represents a bigger challenge to clinicians due to its devastating effects over 
cognitive functions. Still, there is no clear consensus about its appropriate treatment because 
of its complex physiology involving inflammatory responses, neurosteroid-like compounds, 
reactive oxygen species, etc. In addition, there is another layer of complexity represented by 
the co-infections and organ failure that many patients develop in the course of the pathology. 
Nowadays, there had been a lot of attempts to circumvent the signs and symptoms of HE, 
both experimentally and clinically. One example of this is the use of one of the most popular 
anti-inflammatory drugs used to treat cirrhotic patients, infliximab, which reduces peripheral 
inflammation, directly impacts over neuroinflammation, and restores the altered neurotrans-
mission and cognitive impairment, as well as the reversal of activation of microglia and astro-
cyte GABA transporters (GAT1, GAT3). Infliximab also reduces the synthesis and release of 
pro-inflammatory cytokines, such as TNFα, IL-1β, etc., as demonstrated by Dadsetan et al. in 
a murine model of HE [87, 88]. These data are still scarce in human subjects, although some 
advance have been reported. In an initial trial, Sharma and co-workers reported that patients 
with severe alcohol-associated hepatitis, who received a single dose of infliximab (5 mg/kg IV), 
have an improvement of the Maddrey’s discriminant factor (DF)—useful in the prediction of 
short-term prognosis—serum TNFα, C reactive protein (CRP), MELD score and total neutro-
phil count compared with the before-treatment parameters; interestingly, among the patients 
who survived only 8% had HE at admission, while among those who died, 67% suffer from 
HE; the authors concluded that HE at admission of the trial, Lille score and delta bilirubin, 
predicted 2-month mortality and that infliximab should be carefully used to treat alcoholic 
hepatitis [89]. Besides the use of infliximab, other therapies aimed to reduce the production 
of ammonia by the intestinal microbiota, especially the coliforms, have been widely reported. 
Treatment with lactulose (a non-absorbable disaccharide) or non-absorbable antibiotic rifaxi-
min, are two of the most frequent therapies for cirrhotic patients suffering from HE. The meta-
bolic activity of colonic bacteria which produce short-chain organic acids when metabolize 
lactulose lowering the pH of the gastrointestinal tract, is the main effect of the disaccharide 
for the removal of nitrogen; the acidic environment also results in the change of ammonia 
to ammonium (NH
4
+) a non-absorbable form of nitrogen which diminishes the circulating 
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ammonia. Further  mechanisms include the laxative effect for removal of nitrogen-containing 
compounds from the gut. In a concise Cochrane review from last year, 38 clinical trials were 
evaluated and their findings indicate that non-absorbable disaccharides have beneficial effects 
when compared with placebo/no intervention on mortality, HE, liver failure, hepatorenal syn-
drome and variceal bleeding; secondary outcomes such as quality of life, also were favored 
when non-absorbable disaccharides were administered [90]. Additionally, experimental data 
indicates that lactulose promotes neuro- and astrogenesis in the hippocampus of rats with HE 
as well as the reduction of plasma ammonia, the locomotor activity impairment and neuronal 
hyperactivity in brain areas related with locomotor activity [91]. These data are in accordance 
with those data indicating that Lactulose do also improved cognitive function in MHE patients, 
as reviewed by Luo et al. [92]. The non-absorbable antibiotic, rifaximin, is the most common 
additive therapy along with lactulose to treat cirrhotic patients with HE. In a recent prospec-
tive observational study, 60 HE patients were divided into two groups, one receiving rifaximin 
alone and the other one received rifaximin plus lactulose for 7–15 days until discharge from 
hospital or death. In this study, the authors found that both groups were effectively improved 
in their mental scores, although they conclude that the combination of both substances was 
effective, but not superior to lactulose alone in the treatment of HE [93]. The resolution of 
overt HE has also been tested using rifaximin in comparison with other antibiotics. A meta-
analysis of these trials indicates that rifaximin treatment was more likely to resolve an episode 
in patients with OHE besides an improvement in secondary prevention of HE [94]. Other treat-
ment regimes devoted to reduce the serum ammonia levels, such as polyethylene glycol (PEG), 
sodium benzoate, odium phenylacetate, glycerol-phenylbutyrate (GPB), ornithine-phenylac-
etate (OP), phenyl-acetyl-glutamine (PAGN), and a carbon microsphere adsorbent (AST-120) 
among others, had been also tested for nitrogen removal (for a concise review see [95]).
On the other hand, it is more common to see the rise of many biological compounds that previ-
ously were used to treat distinct pathologies; an example of this is Artesunate, a water-soluble 
hemisuccinate derivative of the Chinese herb Artemisia annua, that has been recommended 
for its use as an antimalarial drug, but it seems that also have anti-inflammatory properties 
because its use in cancerous cells inhibits its replication and interferes with the expression of 
pro-inflammatory genes [96, 97]. Artesunate do also have anti-profibrotic properties as was 
demonstrated recently by Wang and colleagues. Here, Wang et al. investigate the role of treat-
ment with artesunate in a lung fibrosis rodent model; the authors found that artesunate treat-
ment successfully reverted the expression of pro-fibrotic genes such as transforming growth 
factor (TGFβ), Smad3, and α-smooth muscle actin (α-SMA) as well as the heat shock protein 
47 (HSP47) at the protein level, when compared with control animals [98]; these results are in 
accordance with those of Wang et al., whose findings in the RLE-6TN cell line indicates that 
TGFβ and Smad3 are inhibited after artesunate exposure [99]. The effect of artesunate on the 
CNS of rats with HE has been tested too. Rats administered with artesunate (50 or 100 mg/kg), 
significantly improved its spatial learning ability in the Morris water maze test, while in vitro, 
cerebellar granule neurons treated with artesunate (100 μM) significantly reduced its glutamate 
release, as well as the Na+K+-ATPase activity, indicating that artesunate has a neuroprotective 
effect, although the effect over astrocytes was not evaluated in this work [100]. Additional evi-
dence about the effect of artesunate over glial cells is lacking, but this drug has a relevant role 
in the field of the HE treatment choices. A synthetic drug called GR3027 has been tested in vivo 
in a rat model of HE. This new compound has antagonist properties over the GABA
A
 receptors 
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when subcutaneously administered and effectively reverses the motor coordination and spatial 
memory impairment in rats with experimental HE, offering a new way to prevent the ammonia-
induced neurological GABA-related damage [101]. These findings are similar to those reported 
by Turkmen et al. using the UC1011 GABA
A
 receptor antagonist, who also observed a reduced 
allopregnanolone effect on the learning test [102].
Although the mechanisms of astrocyte cell swelling are still controversial, some authors pro-
pose that the plasma membrane depolarization plays a crucial role, while others suggest that 
the ionic homeostasis is equally important [103, 104]. In addition, glutamine, manganese, pH 
changes, and the neurosteroids are also implicated in this process. However, both, in vivo and 
in vitro experimental evidence strongly suggests that astrocyte swelling is the primary response 
to hyperammonemia. One additional factor is the oxidative stress derived from the altered 
mitochondria. It has been shown that astrocytes exposed to ammonia, results in the activation 
of the mitochondrial permeability transition pore (MPT), a process related to generation of 
ROS within the cell. The permeability transition is a sudden increase in the inner mitochondrial 
membrane to solutes >1.5 kDa and it is known that adenine nucleotides inhibit this process. 
The MPT is a Ca2+-dependent process that usually culminates in necrosis or apoptosis in hepa-
tocytes; in mammals, cyclophilin D (CyPD) (a conserved cis-trans isomerase) acts as the mito-
chondrial receptor for cyclosporine A (CsA) (a very well-known immunosuppressive agent). 
The MTP is a multiprotein complex whose formation is ultimately inhibited by the CyPD/
CsA complex. Pre-treatment of astrocytes with CsA completely reverts the cell swelling after 
treatment with ammonia [25]; in a similar manner, sodium pyruvate, minocycline, magnesium 
sulfate, and trifluoparazine (TFP), decreased the ammonia-induced MTP-dependent cell swell-
ing, in a significant manner [105]. Other antioxidant compounds have been tested in order to 
revert the cognitive impairment in HE. For example, the multifunctional soy isoflavone, genis-
tein, has an important activity as an oxygen-derived free radicals scavenger, and as a potent 
inhibitor of pro-inflammatory cytokines such as IL-4, IL-10, IL-1β, TNFα, etc., as well as the 
expression of GABA
A
 and GluR2 receptors in the hippocampus of a rat model of HE, restoring 
the altered neurotransmission, neuroinflammation and the DNA damage observed in the rat’s 
brain [106, 107]. Further evidence indicates that genistein may inhibit astrocyte swelling by 
inhibiting the protein tyrosine kinase (PTK) activity and repression of NF-κB-mediated induc-
ible nitric oxide synthase (iNOS)-derived nitric oxide (NO) accumulation [108]. Resveratrol, 
lipoic acid (LA), and N-acetyl-cysteine (NAC) are important anti-oxidants that can, at least in 
vitro, modulate the expression and activity of the glutamate transporters, increase the gluta-
mate release, reduce the activity of GS and GSH content as well as the ammonia-induced pro-
inflammatory response in glial cells [109].
A most recent study, conducted in vivo, indicates that TNFα and its receptors, TNFR1 and 
TNFR2, play major roles in acute ammonia intoxication. In TNFα-deficient or double TNFR1/
TNFR2 knock-out mice, ammonia challenge is unable to trigger astrocyte cell swelling, an 
affect that seems to be related to the expression of the Na+, K+, 2Cl− (NKCCl) co-transporter, 
which is closely related to the NH
4
+ hepatic clearance [110].
L-ornithine and L-aspartate (LOLA) are urea cycle substrates that can lower ammonia levels 
in cirrhotic patients. The first is a substrate of the ornithine-aminotransferase (OAT) enzyme, 
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which converts ornithine into glutamate or glutamate-semialdehyde, while L-aspartate is 
converted by the aspartate-aminotransferase into glutamate or oxaloacetate [5]. A complete 
review about the effect of LOLA in cirrhotic patients has been published and one of the main 
conclusions was that LOLA is effective in patients with OHE and less beneficial for those hav-
ing MHE and had no effects on patients with acute liver failure [111, 112].
An intriguing method to treat liver-affected patients is based in Ayurveda. According to 
Wikipedia, Ayurveda is a system of medicine with roots in India, where medical knowledge 
is transmitted from gods to sages and then to humans. Ayurveda therapies are based on com-
plex herbal compounds, minerals, and metal substances. In a clinical research paper, Ayurveda 
was put into practice to treat a case of HE in India. The report indicates that Ayurvedic ther-
apy, consisting on a mix of four substances (Siddha Makar Dhwaja, Brihat Vata Chintamani Rasa, 
Phyllanthus niruri extract and a syrup of “hepatoprotective herbs”), was administered to a grade 
three HE male patient currently receiving “modern therapies.” After a 3-day period of treatment, 
the patient was found more oriented and awake. The hepatic aminotransferases and biliru-
bin significantly improved after almost 1 month of treatment [113]. This report, according to 
authors, is interesting enough to begin a new debate in the area of practice of Ayurvedic medi-
cine. The debate is open.
4. Concluding remarks
Hepatic encephalopathy is a very devastating disease associated with liver failure. Besides 
the detrimental effects over astrocyte and neuron physiology, HE had a direct impact over 
the quality of life of affected patients. Recent evidence suggests that many pro-inflammatory 
pathways are related to these pathology and therapeutic interventions are devoted to coun-
teract it. In this chapter, many of the molecular and pathological events related with ammo-
nia and its effects over astrocytes cells had been addressed. Indeed, ammonia is one of the 
main factors contributing to the pathophysiology of HE, responsible of the astrocyte swelling 
along with other metabolites such as myoinositol, manganese, etc. (Figure 4). Ammonia is a 
toxic compound mainly produced by the bacteria in the gastrointestinal tract or by metabo-
lism of ammonium-containing substances. In healthy subjects, urea is the final metabolite 
of ammonium metabolism in the liver, which is then excreted in urine. Hepatic failure is a 
one of the most common public concerns in western economies and is beginning to become 
a major problem in the next 10–15 years. Some of the most feasible and easy-to-implement 
therapies against liver disease is prevention. Public health policies must be strengthened 
regarding preventive information not only for liver but also to different metabolic-related ill-
ness. The stress and inappropriate feeding habits in general population has enormous impact 
not only in adults, but also in young or even in elementary-school grade childhood. One of 
the main tasks of public health should be informative and not only the medical practice. If we 
want to succeed in our struggle against different maladies affecting human beings, we must 
to begin to turn the sight to the basics of having a proper balanced diet and to make regular 
physical activity; this actions would improve and prevent any metabolic imbalance in the 
short to median term. The society has the future in their hands.




Carlos Pérez-Monter1,2* and Aldo Torre-Delgadillo1,2
*Address all correspondence to: carlos.perezm@incmnsz.mx
1 Department of Gastroenterology, National Institute of Medical Sciences, Salvador Zubiran, 
Tlalpan, Mexico
2 Faculty of Medicine, National University of Mexico, Ciudad de México, Mexico
References
[1] Ferenci P, Herneth A, Steindl P. Newer approaches to therapy of hepatic encephalopa-
thy. Seminars in Liver Disease. 1996;16(3):329-338
[2] Mullen KD, Prakash RK. New perspectives in hepatic encephalopathy. Clinics in Liver 
Disease. 2012;16(1):1-5
Figure 4. Proposed model of astrocyte dynamic during hyperammonemic conditions. Here, the ammonia (triangle) 
molecules are increased in the extracellular space and they easily diffuse through the plasma membrane or by means 
of the NKCC1 channels (dark gray cylinders) once inside ammonia is conjugated with glutamate (Glu) by the enzyme 
glutamine synthase (not shown) to generate glutamine (Gln). This is the GGC previously described (see Figure 1). In 
hyperammonemic conditions, such as that resulting from liver cirrhosis, the amount of Gln exceeds the astrocyte capacity 
to export it. Then, astrocyte increase the expression of the water channel AQP
4
 (light gray cylinders) in order to let water 
(snow flake-like spots) to get inwards. These process is accompanied by the increase of different interleukines like TNFα, 
IL-1β, IFNγ, and other pro-inflammatory cytokines (IL´s), which promotes the mitochondria to become less effective in 
its metabolic functions, leading the astrocyte to an stressed state. This process generates reactive oxygen species (ROS) 
and reactive nitrosative species (RNS), as well as oxidized RNAs (short lines) that eventually impairs the astrocyte 
overall function. The whole process generates a condition of low-grade cellular edema and astrocyte cell swelling. See 
text for additional details: (NH
4
+), (Glu), (Gln), (dark gray cilinders), (light gray cylinders), (snow flake-like spots).
Astrocyte - Physiology and Pathology224
[3] Nabi E, Bajaj JS. Useful tests for hepatic encephalopathy in clinical practice. Current 
Gastroenterology Reports. 2014;16(1):362
[4] Zhan T, Stremmel W. The diagnosis and treatment of minimal hepatic encephalopathy. 
Deutsches Arzteblatt international. 2012;109(10):180-187
[5] Rose CF. Ammonia-lowering strategies for the treatment of hepatic encephalopathy. 
Clinical Pharmacology and Therapeutics. 2012;92(3):321-331
[6] Wakim-Fleming J. Hepatic encephalopathy: Suspect it early in patients with cirrhosis. 
Cleveland Clinic Journal of Medicine. 2011;78(9):597-605
[7] Khungar V, Poordad F. Hepatic encephalopathy. Clinics in Liver Disease. 2012;16(2):301-320
[8] Zielinska M, Popek M, Albrecht J. Roles of changes in active glutamine transport in 
brain edema development during hepatic encephalopathy: An emerging concept. 
Neurochemical Research. 2014;39(3):599-604
[9] Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemi-
ology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, inci-
dence, and outcomes. Hepatology. 2016;64(1):73-84
[10] Morris SM Jr. Regulation of enzymes of the urea cycle and arginine metabolism. Annual 
Review of Nutrition. 2002;22:87-105
[11] Popoli M, Yan Z, McEwen BS, Sanacora G. The stressed synapse: The impact of stress and 
glucocorticoids on glutamate transmission. Nature Reviews. Neuroscience. 2011;13(1):22-37
[12] Hull J, Hindy ME, Kehoe PG, Chalmers K, Love S, Conway ME. Distribution of the 
branched chain aminotransferase proteins in the human brain and their role in gluta-
mate regulation. Journal of Neurochemistry. 2012;123(6):997-1009
[13] Cardona C, Sanchez-Mejias E, Davila JC, Martin-Rufian M, Campos-Sandoval JA, 
Vitorica J, Alonso FJ, Mates JM, Segura JA, Norenberg MD, et al. Expression of Gls and 
Gls2 glutaminase isoforms in astrocytes. Glia. 2015;63(3):365-382
[14] Hertz L, Song D, Peng L, Chen Y. Multifactorial effects on different types of brain cells 
contribute to ammonia toxicity. Neurochemical Research. 2017;42(3):721-736
[15] Lachmann V, Gorg B, Bidmon HJ, Keitel V, Haussinger D. Precipitants of hepatic 
encephalopathy induce rapid astrocyte swelling in an oxidative stress dependent man-
ner. Archives of Biochemistry and Biophysics. 2013;536(2):143-151
[16] Shawcross D, Jalan R. The pathophysiologic basis of hepatic encephalopathy: 
Central role for ammonia and inflammation. Cellular and Molecular Life Sciences. 
2005;62(19-20):2295-2304
[17] Eefsen M, Jelnes P, Schmidt LE, Vainer B, Bisgaard HC, Larsen FS. Brain expression of 
the water channels aquaporin-1 and -4 in mice with acute liver injury, hyperammonemia 
and brain edema. Metabolic Brain Disease. 2010;25(3):315-323
[18] Blei AT. The pathophysiology of brain edema in acute liver failure. Neurochemistry 
International. 2005;47(1-2):71-77
Astrocyte Pathophysiology in Liver Disease
http://dx.doi.org/10.5772/intechopen.72506
225
[19] Wright G, Soper R, Brooks HF, Stadlbauer V, Vairappan B, Davies NA, Andreola F, 
Hodges S, Moss RF, Davies DC, et al. Role of aquaporin-4 in the development of brain 
oedema in liver failure. Journal of Hepatology. 2010;53(1):91-97
[20] Rama Rao KV, Verkman AS, Curtis KM, Norenberg MD. Aquaporin-4 deletion in 
mice reduces encephalopathy and brain edema in experimental acute liver failure. 
Neurobiology of Disease. 2014;63:222-228
[21] Rama Rao KV, Chen M, Simard JM, Norenberg MD. Increased aquaporin-4 expression 
in ammonia-treated cultured astrocytes. Neuroreport. 2003;14(18):2379-2382
[22] Arima H, Yamamoto N, Sobue K, Umenishi F, Tada T, Katsuya H, Asai K. Hyperosmolar 
mannitol simulates expression of aquaporins 4 and 9 through a p38 mitogen-activated 
protein kinase-dependent pathway in rat astrocytes. The Journal of Biological Chemistry. 
2003;278(45):44525-44534
[23] Thai TL, Blount MA, Klein JD, Sands JM. Lack of protein kinase C-alpha leads to impaired 
urine concentrating ability and decreased aquaporin-2 in angiotensin II-induced hyper-
tension. American journal of physiology Renal physiology. 2012;303(1):F37-F44
[24] Norenberg MD, Rao KV, Jayakumar AR. Mechanisms of ammonia-induced astrocyte 
swelling. Metabolic Brain Disease. 2005;20(4):303-318
[25] Rama Rao KV, Chen M, Simard JM, Norenberg MD. Suppression of ammonia-induced 
astrocyte swelling by cyclosporin A. Journal of Neuroscience Research. 2003;74(6):891-897
[26] Wright G, Shawcross D, Olde Damink SW, Jalan R. Brain cytokine flux in acute liver 
failure and its relationship with intracranial hypertension. Metabolic Brain Disease. 
2007;22(3-4):375-388
[27] Jiang W, Desjardins P, Butterworth RF. Direct evidence for central proinflammatory 
mechanisms in rats with experimental acute liver failure: Protective effect of hypother-
mia. Journal of Cerebral Blood Flow and Metabolism. 2009;29(5):944-952
[28] Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, 
Cryan JF. Ingestion of Lactobacillus strain regulates emotional behavior and central 
GABA receptor expression in a mouse via the vagus nerve. Proceedings of the National 
Academy of Sciences of the United States of America. 2011;108(38):16050-16055
[29] Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: Endogenous danger sig-
naling. Molecular Medicine. 2008;14(7-8):476-484
[30] Yang R, Zou X, Tenhunen J, Tonnessen TI. HMGB1 and extracellular histones signifi-
cantly contribute to systemic inflammation and multiple organ failure in acute liver fail-
ure. Mediators of Inflammation. 2017;2017:5928078
[31] Ohnishi M, Monda A, Takemoto R, Fujimoto Y, Sugitani M, Iwamura T, Hiroyasu T, 
Inoue A. High-mobility group box 1 up-regulates aquaporin 4 expression via microglia-
astrocyte interaction. Neurochemistry International. 2014;75:32-38
[32] Wen Z, Lei Z, Yao L, Jiang P, Gu T, Ren F, Liu Y, Gou C, Li X, Wen T. Circulating histones 
are major mediators of systemic inflammation and cellular injury in patients with acute 
liver failure. Cell Death & Disease. 2016;7(9):e2391
Astrocyte - Physiology and Pathology226
[33] Li X, Gou C, Yao L, Lei Z, Gu T, Ren F, Wen T. Patients with HBV-related acute- on-chronic 
liver failure have increased concentrations of extracellular histones aggravating cellular 
damage and systemic inflammation. Journal of Viral Hepatitis. 2017;24(1):59-67
[34] Allam R, Kumar SV, Darisipudi MN, Anders HJ. Extracellular histones in tissue injury 
and inflammation. Journal of Molecular Medicine. 2014;92(5):465-472
[35] Carson MJ, Thrash JC, Walter B. The cellular response in neuroinflammation: The 
role of leukocytes, microglia and astrocytes in neuronal death and survival. Clinical 
Neuroscience Research. 2006;6(5):237-245
[36] Butterworth RF. The liver-brain axis in liver failure: Neuroinflammation and encepha-
lopathy. Nature Reviews. Gastroenterology & Hepatology. 2013;10(9):522-528
[37] Gorg B, Qvartskhava N, Keitel V, Bidmon HJ, Selbach O, Schliess F, Haussinger D. 
Ammonia induces RNA oxidation in cultured astrocytes and brain in vivo. Hepato logy. 
2008;48(2):567-579
[38] Gorg B, Karababa A, Shafigullina A, Bidmon HJ, Haussinger D. Ammonia-induced 
senescence in cultured rat astrocytes and in human cerebral cortex in hepatic encepha-
lopathy. Glia. 2015;63(1):37-50
[39] Jordens MS, Keitel V, Karababa A, Zemtsova I, Bronger H, Haussinger D, Gorg B. 
Multidrug resistance-associated protein 4 expression in ammonia-treated cultured rat 
astrocytes and cerebral cortex of cirrhotic patients with hepatic encephalopathy. Glia. 2015
[40] Dhiman RK. Gut microbiota and hepatic encephalopathy. Metabolic Brain Disease. 
2013;28(2):321-326
[41] Gupta A, Dhiman RK, Kumari S, Rana S, Agarwal R, Duseja A, Chawla Y. Role of small 
intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic 
patients with minimal hepatic encephalopathy. Journal of Hepatology. 2010;53(5):849-855
[42] Jun DW, Kim KT, Lee OY, Chae JD, Son BK, Kim SH, Jo YJ, Park YS. Association between 
small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients. 
Digestive Diseases and Sciences. 2010;55(5):1465-1471
[43] Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, 
Eisenbarth SC, Jurczak MJ, et al. Inflammasome-mediated dysbiosis regulates progres-
sion of NAFLD and obesity. Nature. 2012;482(7384):179-185
[44] Wei X, Yan X, Zou D, Yang Z, Wang X, Liu W, Wang S, Li X, Han J, Huang L, et al. 
Abnormal fecal microbiota community and functions in patients with hepatitis B liver 
cirrhosis as revealed by a metagenomic approach. BMC Gastroenterology. 2013;13:175
[45] Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, Noble NA, Unser AB, 
Daita K, Fisher AR, et al. Altered profile of human gut microbiome is associated with 
cirrhosis and its complications. Journal of Hepatology. 2014;60(5):940-947
[46] Bajaj JS, Ridlon JM, Hylemon PB, Thacker LR, Heuman DM, Smith S, Sikaroodi M, 
Gillevet PM. Linkage of gut microbiome with cognition in hepatic encephalopathy. American 
Journal of Physiology Gastrointestinal and Liver Physiology. 2012;302(1):G168-G175
Astrocyte Pathophysiology in Liver Disease
http://dx.doi.org/10.5772/intechopen.72506
227
[47] Preveden T, Scarpellini E, Milic N, Luzza F, Abenavoli L. Gut microbiota changes and 
chronic hepatitis C virus infection. Expert Review of Gastroenterology & Hepatology. 
2017;11(9):813-819
[48] Lavoie J, Layrargues GP, Butterworth RF. Increased densities of peripheral-type ben-
zodiazepine receptors in brain autopsy samples from cirrhotic patients with hepatic 
encephalopathy. Hepatology. 1990;11(5):874-878
[49] Ahboucha S, Butterworth RF. The neurosteroid system: Implication in the pathophysiol-
ogy of hepatic encephalopathy. Neurochemistry International. 2008;52(4-5):575-587
[50] Midzak A, Zirkin B, Papadopoulos V. Translocator protein: Pharmacology and steroido-
genesis. Biochemical Society Transactions. 2015;43(4):572-578
[51] Hazell AS, Desjardins P, Butterworth RF. Chronic exposure of rat primary astrocyte cul-
tures to manganese results in increased binding sites for the 'peripheral-type' benzodiaz-
epine receptor ligand 3H-PK 11195. Neuroscience Letters. 1999;271(1):5-8
[52] Cani PD, Everard A, Duparc T. Gut microbiota, enteroendocrine functions and metabo-
lism. Current Opinion in Pharmacology. 2013;13(6):935-940
[53] Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty acids 
in human large intestine, portal, hepatic and venous blood. Gut. 1987;28(10):1221-1227
[54] Nohr MK, Pedersen MH, Gille A, Egerod KL, Engelstoft MS, Husted AS, Sichlau RM, 
Grunddal KV, Poulsen SS, Han S, et al. GPR41/FFAR3 and GPR43/FFAR2 as cosensors 
for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and 
FFAR2 in enteric leukocytes. Endocrinology. 2013;154(10):3552-3564
[55] Foster AC, Kemp JA. Glutamate- and GABA-based CNS therapeutics. Current Opinion 
in Pharmacology. 2006;6(1):7-17
[56] Kinsner A, Pilotto V, Deininger S, Brown GC, Coecke S, Hartung T, Bal-Price A.  nflam-
matory neurodegeneration induced by lipoteichoic acid from Staphylococcus aureus is 
mediated by glia activation, nitrosative and oxidative stress, and caspase activation. 
Journal of Neurochemistry. 2005;95(4):1132-1143
[57] Feinberg AP, Tycko B. The history of cancer epigenetics. Nature Reviews Cancer. 
2004;4(2):143-153
[58] Qiang M, Rani CS, Ticku MK. Neuron-restrictive silencer factor regulates the N-methyl-
D-aspartate receptor 2B subunit gene in basal and ethanol-induced gene expression in 
fetal cortical neurons. Molecular Pharmacology. 2005;67(6):2115-2125
[59] Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: MicroRNA 
biogenesis pathways and their regulation. Nature Cell Biology. 2009;11(3):228-234
[60] Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: Insights into functions. 
Nature Reviews Genetics. 2009;10(3):155-159
[61] Sepramaniam S, Ying LK, Armugam A, Wintour EM, Jeyaseelan K. MicroRNA-130a 
represses transcriptional activity of aquaporin 4 M1 promoter. The Journal of Biological 
Chemistry. 2012;287(15):12006-12015
Astrocyte - Physiology and Pathology228
[62] Sepramaniam S, Armugam A, Lim KY, Karolina DS, Swaminathan P, Tan JR, Jeyaseelan K. 
MicroRNA 320a functions as a novel endogenous modulator of aquaporins 1 and 4 
as well as a potential therapeutic target in cerebral ischemia. The Journal of Biological 
Chemistry. 2010;285(38):29223-29230
[63] Oenarto J, Karababa A, Castoldi M, Bidmon HJ, Gorg B, Haussinger D. Ammonia-induced 
miRNA expression changes in cultured rat astrocytes. Scientific Reports. 2016;6:18493
[64] Silva VR, Secolin R, Vemuganti R, Lopes-Cendes I, Hazell AS. Acute liver failure is asso-
ciated with altered cerebral expression profiles of long non-coding RNAs. Neuroscience 
Letters. 2017;656:58-64
[65] Strange K. Cellular volume homeostasis. Advances in Physiology Education. 2004;28(1-4): 
155-159
[66] Cordoba J, Gottstein J, Blei AT. Glutamine, myo-inositol, and organic brain osmolytes 
after portocaval anastomosis in the rat: Implications for ammonia-induced brain edema. 
Hepatology. 1996;24(4):919-923
[67] Liang J, Deng X, Lin ZX, Zhao LC, Zhang XL. Attenuation of portal hypertension by 
natural taurine in rats with liver cirrhosis. World Journal of Gastroenterology. 2009; 
15(36):4529-4537
[68] Invernizzi P, Setchell KD, Crosignani A, Battezzati PM, Larghi A, O'Connell NC, Podda M. 
Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine- 
conjugated species in patients with primary biliary cirrhosis. Hepatology. 1999;29(2):320-327
[69] Swain MS, Bergeron M, Audet R, Blei AT, Butterworth RF. Monitoring of neurotransmit-
ter amino acids by means of an indwelling cisterna magna catheter: A comparison of two 
rodent models of fulminant liver failure. Hepatology. 1992;16(4):1028-1035
[70] Bosman DK, Deutz NE, Maas MA, van Eijk HM, Smit JJ, de Haan JG, Chamuleau RA. 
Amino acid release from cerebral cortex in experimental acute liver failure, studied by 
in vivo cerebral cortex microdialysis. Journal of Neurochemistry. 1992;59(2):591-599
[71] Swain M, Butterworth RF, Blei AT. Ammonia and related amino acids in the pathogen-
esis of brain edema in acute ischemic liver failure in rats. Hepatology. 1992;15(3):449-453
[72] Hagberg H, Lehmann A, Sandberg M, Nystrom B, Jacobson I, Hamberger A. Ischemia-
induced shift of inhibitory and excitatory amino acids from intra- to extracellular com-
partments. Journal of Cerebral Blood Flow and Metabolism. 1985;5(3):413-419
[73] Heins J, Zwingmann C. Organic osmolytes in hyponatremia and ammonia toxicity. 
Metabolic Brain Disease. 2010;25(1):81-89
[74] Pasantes Morales H, Schousboe A. Volume regulation in astrocytes: A role for taurine as 
an osmoeffector. Journal of Neuroscience Research. 1988;20(4):503-509
[75] Hamed SA, Hamed EA, Zakary MM. Oxidative stress and S-100B protein in children 
with bacterial meningitis. BMC Neurology. 2009;9:51
[76] Zenaide PV, Gusmao-Flores D. Biomarkers in septic encephalopathy: A systematic 
review of clinical studies. Revista Brasileira de Terapia Intensiva. 2013;25(1):56-62
Astrocyte Pathophysiology in Liver Disease
http://dx.doi.org/10.5772/intechopen.72506
229
[77] Adami C, Sorci G, Blasi E, Agneletti AL, Bistoni F, Donato R. S100B expression in and 
effects on microglia. Glia. 2001;33(2):131-142
[78] Duarte-Rojo A, Ruiz-Margain A, Macias-Rodriguez RU, Cubero FJ, Estradas-Trujillo J, 
Munoz-Fuentes RM, Torre A. Clinical scenarios for the use of S100beta as a marker of 
hepatic encephalopathy. World Journal of Gastroenterology. 2016;22(17):4397-4402
[79] Saleh A, Kamel L, Ghali A, Ismail A, El Khayat H. Serum levels of astroglial S100-beta 
and neuron-specific enolase in hepatic encephalopathy patients. Eastern Mediterranean 
Health Journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah 
li-sharq al-mutawassit. 2007;13(5):1114-1123
[80] Wiltfang J, Nolte W, Otto M, Wildberg J, Bahn E, Figulla HR, Pralle L, Hartmann H, 
Ruther E, Ramadori G. Elevated serum levels of astroglial S100beta in patients with liver 
cirrhosis indicate early and subclinical portal-systemic encephalopathy. Metabolic Brain 
Disease. 1999;14(4):239-251
[81] Cordoba J, Sanpedro F, Alonso J, Rovira A. 1H magnetic resonance in the study of 
hepatic encephalopathy in humans. Metabolic Brain Disease. 2002;17(4):415-429
[82] Feruglio FS, Migheli B, Campus S, Pandol Fo G, Bert G, Pupita F. Hemodynamic and met-
abolic aspects of the cerebral circulation in hepatic cirrhosis. Minerva Cardioangiologica. 
1961;9:429-431
[83] Bianchi Porro G, Maiolo AT, Della Porta P. Cerebral blood flow and metabolism in 
hepatic cirrhosis before and after portacaval shunt operation. Gut. 1969;10(11):894-897
[84] Macias-Rodriguez RU, Duarte-Rojo A, Cantu-Brito C, Sauerbruch T, Ruiz-Margain A, 
Trebicka J, Green-Gomez M, Diaz Ramirez JB, Sierra Beltran M, Uribe-Esquivel M, et al. 
Cerebral haemodynamics in cirrhotic patients with hepatic encephalopathy. Liver 
International. 2015;35(2):344-352
[85] Oncel C, Yilmaz M. Cerebral hemodynamics in patients with cirrhosis. The Turkish 
Journal of Gastroenterology: The Official Journal of Turkish Society of Gastroenterology. 
2016;27(3):264-267
[86] Zhou Y, Dong Q, Zhang R, Zhou S, Li L, Cheng K, Kong R, Yu Q, Xu S, Li J, et al. Cerebral 
hemodynamics and cognitive function in cirrhotic patients with hepatic encephalopa-
thy. Gastroenterology Research and Practice. 2016;2016:8485032
[87] Dadsetan S, Balzano T, Forteza J, Agusti A, Cabrera-Pastor A, Taoro-Gonzalez L, 
Hernandez-Rabaza V, Gomez-Gimenez B, ElMlili N, Llansola M, et al. Infliximab 
reduces peripheral inflammation, neuroinflammation, and extracellular GABA in the 
cerebellum and improves learning and motor coordination in rats with hepatic encepha-
lopathy. Journal of Neuroinflammation. 2016;13(1):245
[88] Dadsetan S, Balzano T, Forteza J, Cabrera-Pastor A, Taoro-Gonzalez L, Hernandez-Rabaza V, 
Gil-Perotin S, Cubas-Nunez L, Garcia-Verdugo JM, Agusti A, et al. Reducing peripheral 
inflammation with infliximab reduces neuroinflammation and improves cognition in rats 
with hepatic encephalopathy. Frontiers in Molecular Neuroscience. 2016;9:106
[89] Sharma P, Kumar A, Sharma BC, Sarin SK. Infliximab monotherapy for severe alco-
holic hepatitis and predictors of survival: An open label trial. Journal of Hepatology. 
2009;50(3):584-591
Astrocyte - Physiology and Pathology230
[90] Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no 
intervention and lactulose versus lactitol for the prevention and treatment of hepatic 
encephalopathy in people with cirrhosis. The Cochrane Database of Systematic 
Reviews. 2016;4:CD003044
[91] Yang N, Liu H, Jiang Y, Zheng J, Li DM, Ji C, Liu YY, Zuo PP. Lactulose enhances 
neuroplasticity to improve cognitive function in early hepatic encephalopathy. Neural 
Regeneration Research. 2015;10(9):1457-1462
[92] Luo M, Li L, Lu CZ, Cao WK. Clinical efficacy and safety of lactulose for minimal 
hepatic encephalopathy: A meta-analysis. European Journal of Gastroenterology & 
Hepatology. 2011;23(12):1250-1257
[93] Ahire K, Sonawale A. Comparison of Rifaximin plus lactulose with the lactulose 
alone for the treatment of hepatic encephalopathy. The Journal of the Association of 
Physicians of India. 2017;65(8):42-46
[94] Kimer N, Krag A, Moller S, Bendtsen F, Gluud LL. Systematic review with meta-analysis: 
The effects of rifaximin in hepatic encephalopathy. Alimentary Pharmacology & 
Therapeutics. 2014;40(2):123-132
[95] Rahimi RS, Rockey DC. Novel ammonia-lowering agents for hepatic encephalopathy. 
Clinics in Liver Disease. 2015;19(3):539-549
[96] Karpel-Massler G, Westhoff MA, Kast RE, Dwucet A, Nonnenmacher L, Wirtz CR, 
Debatin KM, Halatsch ME. Artesunate enhances the antiproliferative effect of temo-
zolomide on U87MG and A172 glioblastoma cell lines. Anti-Cancer Agents in Medicinal 
Chemistry. 2014;14(2):313-318
[97] Xu H, He Y, Yang X, Liang L, Zhan Z, Ye Y, Yang X, Lian F, Sun L. Anti-malarial agent 
artesunate inhibits TNF-alpha-induced production of proinflammatory cytokines via 
inhibition of NF-kappaB and PI3 kinase/Akt signal pathway in human rheumatoid 
arthritis fibroblast-like synoviocytes. Rheumatology. 2007;46(6):920-926
[98] Wang C, Xuan X, Yao W, Huang G, Jin J. Anti-profibrotic effects of artesunate on 
bleomycin-induced pulmonary fibrosis in Sprague Dawley rats. Molecular Medicine 
Reports. 2015;12(1):1291-1297
[99] Wang CM, Chen J, Jiang M, Xuan XP, Li HX. Relationship between artesunate influence 
on the process of TGF-beta1 induced alveolar epithelial cells transform into mesenchy-
mal cells and on idiopathic pulmonary fibrosis. Yao xue xue bao = Acta pharmaceutica 
Sinica. 2014;49(1):142-147
[100] Wu YB, Zhang L, Li WT, Yang Y, Zhao JM. Artesunate restores spatial learning of 
rats with hepatic encephalopathy by inhibiting ammonia-induced oxidative damage 
in neurons and dysfunction of glutamate signaling in astroglial cells. Biomedicine & 
Pharmacotherapy = Biomedecine & Pharmacotherapie. 2016;84:972-978
[101] Johansson M, Agusti A, Llansola M, Montoliu C, Stromberg J, Malinina E, Ragagnin G, 
Doverskog M, Backstrom T, Felipo V. GR3027 antagonizes GABAA receptor-potentiating 
neurosteroids and restores spatial learning and motor coordination in rats with chronic 
Astrocyte Pathophysiology in Liver Disease
http://dx.doi.org/10.5772/intechopen.72506
231
hyperammonemia and hepatic encephalopathy. American Journal of Physiology 
Gastrointestinal and Liver Physiology. 2015;309(5):G400-G409
[102] Turkmen S, Lundgren P, Birzniece V, Zingmark E, Backstrom T, Johansson IM. 
3beta-20beta-dihydroxy-5alpha-pregnane (UC1011) antagonism of the GABA potentia-
tion and the learning impairment induced in rats by allopregnanolone. The European 
Journal of Neuroscience. 2004;20(6):1604-1612
[103] Allert N, Koller H, Siebler M. Ammonia-induced depolarization of cultured rat cortical 
astrocytes. Brain Research. 1998;782(1-2):261-270
[104] Norenberg MD. Astrocytes and ammonia in hepatic encephalopathy. In: Vellis JD, 
editor. Neuroglia in the Aging Brain. 1st ed. Vol. XIII. New York: Springer Science + 
Business Media, Humana Press; 2002. p. 513
[105] Reddy PV, Rama Rao KV, Norenberg MD. Inhibitors of the mitochondrial permeabil-
ity transition reduce ammonia-induced cell swelling in cultured astrocytes. Journal of 
Neuroscience Research. 2009;87(12):2677-2685
[106] Ganai AA, Husain M. Genistein alleviates neuroinflammation and restores cognitive 
function in rat model of hepatic encephalopathy: Underlying mechanisms. Molecular 
Neurobiology. 2017
[107] Ganai AA, Husain M. Genistein attenuates D-GalN induced liver fibrosis/chronic 
liver damage in rats by blocking the TGF-beta/Smad signaling pathways. Chemico-
Biological Interactions. 2017;261:80-85
[108] Dai H, Jia G, Wang W, Liang C, Han S, Chu M, Mei X. Genistein inhibited ammonia 
induced astrocyte swelling by inhibiting NF-kappaB activation-mediated nitric oxide 
formation. Metabolic Brain Disease. 2017;32(3):841-848
[109] Bobermin LD, Hansel G, Scherer EB, Wyse AT, Souza DO, Quincozes-Santos A, 
Goncalves CA. Ammonia impairs glutamatergic communication in astroglial cells: 
Protective role of resveratrol. Toxicology In Vitro: An International Journal Published 
in Association with BIBRA. 2015;29(8):2022-2029
[110] Pozdeev VI, Lang E, Gorg B, Bidmon HJ, Shinde PV, Kircheis G, Herebian D, Pfeffer K, 
Lang F, Haussinger D, et al. TNFalpha induced up-regulation of Na+, K+, 2Cl− cotrans-
porter NKCC1 in hepatic ammonia clearance and cerebral ammonia toxicity. Scientific 
Reports. 2017;7(1):7938
[111] Acharya SK, Bhatia V, Sreenivas V, Khanal S, Panda SK. Efficacy of L-ornithine 
L-aspartate in acute liver failure: A double-blind, randomized, placebo-controlled 
study. Gastroenterology. 2009;136(7):2159-2168
[112] Jiang Q, Jiang XH, Zheng MH, Chen YP. L-ornithine-l-aspartate in the management of 
hepatic encephalopathy: A meta-analysis. Journal of Gastroenterology and Hepatology. 
2009;24(1):9-14
[113] Rastogi S, Srivastav PS. Ayurveda in critical care: Illustrating Ayurvedic intervention in 
a case of hepatic encephalopathy. Ayu. 2011;32(3):345-348
Astrocyte - Physiology and Pathology232
